146552-71-8

Basic information

• Product Name: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI);(S)-tert-butyl 1-aminopropan-2-ylcarbamate;tert-butyl N-[(2S)-1-aMinopropan-2-yl]carbaMate;N-((S)-2-Amino-1-methylethyl)carbamic acid tert-butyl ester;tert-Butyl ((S)-1-aminopropan-2-yl)carbamate;(S)-2-N-Boc-propane-1,2-diaMine;CarbaMic acid, N-[(1S)-2-aMino-1-Methylethyl]-, 1,1-diMethylethyl ester;Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester
• CAS NO: 146552-71-8
• Molecular Formula: C₈H₁₈N₂O₂
• Molecular Weight: 174.24072
• Product Categories: N-BOC
• Mol File: 146552-71-8.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 264℃
• Flash Point: 113℃
• Appearance: /
• Density: 0.984
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.19±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(146552-71-8)
• EPA Substance Registry System: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(146552-71-8)

Safety Data

• Hazardous Substances Data: 146552-71-8(Hazardous Substances Data)

Usage

General Description

Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is a chemical compound also known as tert-butyl (S)-carbamate. It is commonly used as a reagent in organic synthesis and as a protecting group for amines in peptide synthesis. Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is a colorless to pale yellow liquid at room temperature and is soluble in organic solvents. It can be hazardous if ingested, inhaled, or if it comes into contact with the skin or eyes, and should be handled with care and according to proper safety protocols.

Upstream product

• 78981-25-6 tert-butyl (1S)-2-amino-1-methyl-2-oxoethylcarbamate 
• 109208-68-6 Boc-Ala-O-COO-isoBu 
• 15761-38-3 L-N-Boc-Ala 
• 28875-17-4 (S)-N-(tert-butoxycarbonyl)alanine methyl ester 
• 126301-16-4 (2S)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 146610-69-7 1-azido-(S)-2-(N-tert-butoxycarbonyl)aminopropane 
• 15967-72-3 (S)-1,2-diaminopropane 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 19777-66-3 (S)-propane-1,2-diamine dihydrochloride 
• 824399-47-5 t-butyl (S)-2-{[3-cyano-2-(3,5-dimethoxyphenylamino)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino}-1-methylethylcarbamate 
• 1217317-62-8 (S)-benzyl tert-butyl propane-1,2-diyldicarbamate 
• 1188301-70-3 (S)-tert-butyl 1-(4-(4-bromo-2-(4-trifluoromethyl)phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 882419-75-2 tert-butyl N-[2-(benzylamino)-1-methyl-ethyl]carbamate 
• 1353576-48-3 (S)-methyl 1-(4-(4-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate trifluoroacetate 
• 1353576-51-8 (S)-tert-butyl-1-(4-(4-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropyloxazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353576-45-0 (S)-tert-butyl 1-(4-(4-(2-chloro-5-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353576-40-5 (S)-tert-butyl 1-(4-(2-tert-butyl-4-(2-chloro-5-fluoro-3-(methylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1301178-01-7 C₂₉H₃₉BrN₄O₃ 
• 294648-89-8 C₂₉H₃₇N₇O₂ 
• 735273-02-6 (S,S)-{2-[2-tert-butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-1-methyl-ethyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists

Abstract The optimization efforts that led to a novel series of methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones that are potent rat and human P2X7 antagonists are described. These efforts resulted in the discovery of co